Clinical Trials on Breast in Japan

Total 239 results

Bristol-Myers Squibb

Completed

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer

Breast Cancer

Japan
Japan Breast Cancer Research Group
Eisai Co., Ltd.

Recruiting

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Breast Cancer

Japan
Japan Breast Cancer Research Group
Chugai Pharmaceutical

Unknown

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PRECIOUS)

HER2-positive Locally Advanced or Metastatic Breast Cancer

Japan
Eli Lilly and Company

Completed

Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen

Metastatic Breast Cancer

Japan
Daiichi Sankyo Co., Ltd.
AstraZeneca

Completed

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Malignant Neoplasm of Breast

Japan
Novartis Pharmaceuticals

Completed

A Phase I Study of LFA102 in Japanese Patients

Castration-resistant Prostate Cancer, Advanced Breast Cancer

Japan
Japan Breast Cancer Research Network

Completed

Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer

Breast Neoplasms

Japan
Eli Lilly and Company

Completed

Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer

Metastatic Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Eli Lilly and Company

Terminated

A Study of LY3435151 in Participants With Solid Tumors

Hepatocellular Carcinoma | Solid Tumor | Gastric Adenocarcinoma | Leiomyosarcoma | Head and Neck Squamous Cell Carcinoma | Cervical Carcinoma | Triple-negative Breast Cancer | Undifferentiated Pleomorphic Sarcoma | High Grade Serous Ovarian Carcinoma

United States, Japan
Novartis Pharmaceuticals

Completed

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

NON-breast HER2+ Malignancies

United States, Italy, Korea, Republic of, Japan
Novartis Pharmaceuticals

Terminated

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Advanced or Metastatic ER+ Breast Cancer

United States, France, Germany, Singapore, Italy, Japan, Belgium
Hekabio

Completed

Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan

Breast Cancer | Head and Neck Cancer

Japan
AstraZeneca

Completed

Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

Breast Cancer

Japan
Pfizer

Active, not recruiting

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Neoplasms | Breast Neoplasms

Japan
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Advanced Breast Cancer

Japan
Pfizer

Completed

Study Of Sunitinib With Capecitabine In Breast Cancer

Advanced/Metastatic Breast Cancer

Japan
Pfizer

Completed

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Breast Cancer

Japan
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Triple Negative Breast Cancer (TNBC)

Netherlands, Spain, Hong Kong, Singapore, Italy, Australia, Israel, Japan, United States
Federal University of São Paulo
Emory University; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; University... and other collaborators

Active, not recruiting

Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammatory Markers in Breast Cancer Patients (INFLAMMATE)

Breast Cancer

Brazil, Canada, Italy, Japan
Kyoto Breast Cancer Research Network
Pfizer

Completed

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female

Taiwan, Japan, Korea, Republic of, Australia, Hong Kong
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo, Inc.

Completed

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Japan
Pfizer

Active, not recruiting

A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

Breast Cancer

Japan, Korea, Republic of, Taiwan
R-Pharm

Completed

A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline

Metastatic Breast Cancer

Japan
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Breast Cancer

United States, Japan, Puerto Rico
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)

Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast Cancer

Japan
Novartis Pharmaceuticals

Completed

PCA062 in pCAD-positive Tumors.

Esophageal Cancer | Triple Negative Breast Cancer | Head & Neck Cancer

France, Singapore, Italy, Japan, United States, Spain
Heidelberg University
Siemens Medical Solutions

Completed

Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions

Breast Neoplasms

Germany, United States, France, Japan, Netherlands, Portugal
AstraZeneca
Daiichi Sankyo, Inc.

Completed

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Breast Cancer

United States, Germany, Italy, Korea, Republic of, United Kingdom, Portugal, Australia, Japan, Canada, France
Novartis Pharmaceuticals

Completed

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Japan, Hong Kong, Singapore
Pfizer

Completed

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Neoplasms | Breast Neoplasms

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Pfizer
Japan Breast Cancer Research Group (JBCRG)

Completed

Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy (JBCRG-26)

Breast Cancer

Japan
Ludwig Institute for Cancer Research
Mie University

Completed

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

Stomach Cancer | Breast Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer

Japan
Takeda

Completed

A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer

Premenopausal Breast Cancer

Japan
AstraZeneca

Completed

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg (FINDER I)

Advanced Breast Cancer | Metastatic Breast Cancer

Japan
Pfizer

Recruiting

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Breast Cancer

Japan
Eisai Co., Ltd.

Active, not recruiting

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Breast Neoplasms

Japan
AstraZeneca

Completed

Lynparza Breast Cancer Clinical Experience Investigation

Breast Cancer

Japan
National Cancer Center, Japan
Pfizer; Korean Cancer Study Group

Active, not recruiting

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY (PATHWAY)

Breast Neoplasms

Korea, Republic of, Singapore, Japan, Taiwan
Kyowa Kirin Co., Ltd.

Completed

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Advanced or Recurrent Breast Cancer

Japan
AstraZeneca

Completed

Faslodex Specific Clinical Experience Investigation

Breast Cancer

Japan
Hoffmann-La Roche

Terminated

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)

Breast Cancer

United States, Brazil, Australia, Canada, Japan, Korea, Republic of, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Triple-negative Breast Cancer

Belgium, Italy, Japan, Taiwan, United States, Australia, Singapore, Spain, Germany, Korea, Republic of, Argentina, Canada, France, Hungary, Israel, Lebanon, Thailand
AstraZeneca

Recruiting

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

Breast Cancer

Japan
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast Cancer

United States, Japan
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients (BEECH)

Advanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast Cancer

Canada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
Eisai Inc.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Breast Cancer

United States, Japan
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom

3

Subscribe